Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Avalo Therapeutics's Enterprise Value is $909.74 Mil.
Avalo Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-59.69 Mil. Therefore, Avalo Therapeutics's EV-to-OCF for today is -15.24.
The historical rank and industry rank for Avalo Therapeutics's EV-to-OCF or its related term are showing as below:
AVTX'
s EV-to-OCF Range Over the Past 10 Years
Min: -76.26 Med: -1.36 Max: 13.43
Current: -15.24
During the past 13 years, the highest EV-to-OCF of Avalo Therapeutics was 13.43. The lowest was -76.26. And the median was -1.36.
AVTX's EV-to-OCF is ranked better than 76.74% of 1410
companies
in the Biotechnology industry
Industry Median: -3.475
vs AVTX: -15.24
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avalo Therapeutics's PE Ratio (TTM) for today is calculated as:
Avalo Therapeutics's share price for today is $18.74.
Avalo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Avalo Therapeutics EV-to-OCF Related Terms
Avalo Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Avalo Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avalo Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalo Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's EV-to-OCF falls into.
Avalo Therapeutics's current Enterprise Value is $909.74 Mil.
Avalo Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalo Therapeutics (AVTX) has a EV-to-OCF of -15.24 as of Aug. 05, 2026. According to the industry distribution chart, Avalo Therapeutics ranks #328 out of 1410 companies in the Biotechnology industry, placing it in the top 23.3%.
Is Avalo Therapeutics' EV-to-OCF too high?
Avalo Therapeutics' current EV-to-OCF is -15.24. Based on the distribution chart, Avalo Therapeutics ranks #328 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' EV-to-OCF compare to MRVI and LBRX?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #328 out of 1410 companies for EV-to-OCF. This places Avalo Therapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Avalo Therapeutics's current EV-to-OCF is -15.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $18.74 — trading 62366.7% above its estimated fair value. The current EV-to-OCF is -15.24. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current EV-to-OCF is -15.24 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avalo Therapeutics (AVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued.
The current stock price of $18.74 is trading 62366.7% above its estimated GF Value™ of $0.03.
GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.
Key valuation signals for AVTX:
EV-to-OCF: -15.24
GF Value™: $0.03 vs. price of $18.74 (62366.7% above fair value)
No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score
Get the complete analysis for AVTX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVTX has been successfully added to your 
